Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6:92. https://doi.org/10.1038/s41572-020-00224-3

Article  PubMed  PubMed Central  Google Scholar 

Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915–1928. https://doi.org/10.1016/S0140-6736(19)32591-7

Article  CAS  PubMed  Google Scholar 

Cohen EEW, Soulières D, Le Tourneau C et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393:156–167. https://doi.org/10.1016/S0140-6736(18)31999-8

Article  CAS  PubMed  Google Scholar 

Ferris RL, Blumenschein G, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867. https://doi.org/10.1056/nejmoa1602252

Article  PubMed  PubMed Central  Google Scholar 

Keytruda PD-LTS, MERCK (2023) https://www.keytrudahcp.com/biomarker-testing/pd-l1/ Accessed 31 Aug 2023

Moehler MH, Kato K, Arkenau H-T et al (2023) Rationale 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). J Clin Oncol JCO 41:286

Article  Google Scholar 

Nenclares P, Rullan A, Tam K, Dunn LA, St John M, Harrington KJ (2022) Introducing checkpoint inhibitors into the curative setting of head and neck cancers: lessons learned, future considerations. Am Soc Clin Oncol Educ Book 42:1–16. https://doi.org/10.1200/edbk_351336

Article  PubMed  Google Scholar 

Uppaluri R, Campbell KM, Egloff AM et al (2020) Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated Head and neck cancer: a multicenter, phase II trial. Clin Cancer Res 26:5140–5152. https://doi.org/10.1158/1078-0432.ccr-20-1695

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wise-Draper TM, Gulati S, Palackdharry S et al (2022) Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res 28:1345–1352. https://doi.org/10.1158/1078-0432.ccr-21-3351

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uppaluri R, Lee NY, Westra W et al (2019) KEYNOTE-689: phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma. J Clin Oncol JCO 37:TPS6090. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS6090

Article  Google Scholar 

Zech HB, Moeckelmann N, Boettcher A et al (2020) Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma. Future Oncol 16:3035–3043. https://doi.org/10.2217/fon-2020-0595

Article  CAS  PubMed  Google Scholar 

Lee NY, Ferris RL, Psyrri A et al (2021) Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 22:450–462. https://doi.org/10.1016/s1470-2045(20)30737-3

Article  CAS  PubMed  Google Scholar 

Tao Y, Biau J, Sun XS et al (2023) Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol 34:101–110. https://doi.org/10.1016/j.annonc.2022.10.006

Article  CAS  PubMed  Google Scholar 

Machiels JPTY, Burtness B et al (2022) Primary results of the phase 3 keynote-412 study: pembrolizumab plus chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma. ESMO Congress Abstract LBA5

Bourhis J et al (2021) Avelumab-Cetuximab-Radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial. ESMO Virtual Congress LBA35

Tosi A, Parisatto B, Menegaldo A et al ( 2022) The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors. J Exp Clin Cancer Res 41:279. https://doi.org/10.1186/s13046-022-02481-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Sun H, Zeng Q et al (2019) HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci Rep 9:13404. https://doi.org/10.1038/s41598-019-49771-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Succaria F, Kvistborg P, Stein JE et al (2021) Characterization of the Tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. Cancer Immunol Immunother 70:1227–1237.

Article  CAS  PubMed  Google Scholar 

Compendium, Keytruda RA (2023) https://compendium.ch/product/1346803-keytruda-inf-konz-100-mg-4ml Accessed 19 Aug 2023

Food US, Administration D (2019) FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma RA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-first-line-treatment-head-and-neck-squamous-cell-carcinoma#:~:text=squamous%20cell%20carcinoma Accessed 19 Aug 2023

Food US, Administration D (2016) Pembrolizumab (KEYTRUDA) RA https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda Accessed 19 Aug 2023

European Medicines Agency, Keytruda RA (2023) https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda Accessed 19 Aug 2023

Food US, Administration D. Nivolumab for SCCHN (2023) https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn Accessed 2 Sept 2023

European Medicines Agency, Opdivo (2023) https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo Accessed 2 Sept 2023

Compendium, Opdivo (2023) https://compendium.ch/product/1379284-opdivo-inf-konz-240-mg-24ml Acessed 2 Sept 2023

Park BJ, Mattox AK, Clayburgh D et al (2022) Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck. Oral Oncol 135:106183. https://doi.org/10.1016/j.oraloncology.2022.106183

Article  CAS  PubMed  Google Scholar 

Karabajakian A, Bouaoud J, Michon L et al (2021) Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. Oral Oncol 119:105368. https://doi.org/10.1016/j.oraloncology.2021.105368

Article  CAS  PubMed  Google Scholar 

Jones D, Pereira ER, Padera TP (2018) Growth and immune evasion of lymph node metastasis. Front Oncol 8:36. https://doi.org/10.3389/fonc.2018.00036

Article  PubMed  PubMed Central  Google Scholar 

Ambrosini-Spaltro A, Limarzi F, Gaudio M, Calpona S, Meccariello G (2022) PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis. Virchows Arch 481:93–99. https://doi.org/10.1007/s00428-022-03322-7

Article  CAS  PubMed  Google Scholar 

Kaur A, Kuchta K, Watkin W et al (2023) Programmed death ligand-1 combined positive score concordance and interrater reliability in primary tumors and synchronous lymph node metastases in resected cases of p16+ oropharyngeal squamous cell carcinoma. Arch Pathol Lab Med 147:442–450. https://doi.org/10.5858/arpa.2021-0464-oa

Article  PubMed  Google Scholar 

Kalpakoff M, Hund S, Musser J et al (2021) Intrapatient tumor heterogeneity in IHC Interpretation using PD-L1 IHC 22C3 pharmDx. Appl Immunohistochem Mol Morphol 29:667–673. https://doi.org/10.1097/pai.0000000000000941

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Keukeleire SJ, Vermassen T, Deron P et al (2022) Concordance, correlation, and clinical impact of standardized PD-L1 and TIL scoring in SCCHN. Cancers (Basel) 14:2431. https://doi.org/10.3390%2Fcancers14102431

Article  PubMed  Google Scholar 

Rasmussen JH, Lelkaitis G, Håkansson K et al (2019) Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. Br J Cancer 120:1003–1006. https://doi.org/10.1038/s41416-019-0449-y

Article  PubMed  PubMed Central  Google Scholar 

Paintal AS, Brockstein BE (2020) PD-L1 CPS scoring accuracy in small biopsies and aspirate cell blocks from patients with head and neck squamous cell carcinoma. Head Neck Pathol 14:657–665. https://doi.org/10.1007/s12105-019-01097-z

Article  PubMed  Google Scholar 

Liu Z, Williams M, Stewart J, Glisson BS, Fuller C, Roy-Chowdhuri S (2022) Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma. Cancer Cytopathol 130:110–119. https://doi.org/10.1002/cncy.22501

Article  CAS  PubMed  Google Scholar 

Heidarian A, Wenig BM, Hernandez-Prera JC (2022) Evaluation of programmed death ligand 1 immunohistochemistry in cytology specimens of head and neck squamous cell carcinoma. Cancer Cytopathol 130(2):91. https://doi.org/10.1002/cncy.22500

Article  CAS  PubMed  Google Scholar 

Koomen BM, van der Starre-Gaal J, Vonk JM et al (2021) Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer. Cancer Cytopathol 129:304–317. https://doi.org/10.1002/cncy.22383

Article  CAS  PubMed  Google Scholar 

Fasano M, Corte CMD, Liello RD et al (2022) Immunotherapy for head and neck cancer: present and future. Crit Rev Oncol Hematol 174:103679. https://doi.org/10.1016/j.critrevonc.2022.103679

Article  PubMed  Google Scholar 

Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL, Bruno TC (2023) Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer 23:173–188. https://doi.org/10.1038/s41568-022-00531-9

Article  CAS  PubMed  Google Scholar 

Hirsch FR, McElhinny A, Stanforth D et al (2017) PD-L1 immunohistochemistry assays fo